21211 results about "Hydroxy compound" patented technology

Coating compounds curable by means of high-energy radiation, comprising as binderA) at least one (meth)acrylic copolymer containing olefinic double bonds capable of free-radical polymerization and hydroxyl groups with a C=C equivalent weight from 100 to 10,000 and an OH-value from 20 to 250 mg KOH / g, which is prepared from monomers comprising:A1) at least one olefinically unsaturated, epoxy-functional monomer capable of free-radical polymerization,A2) at least one olefinically unsaturated, carboxy-functional monomer capable of free-radical polymerization andA3) at least one further olefinically unsaturated monomer capable of free-radical polymerization which is different from A1) and A2), andB) at least one component with free isocyanate groups and process for multilayer coating using the coating compounds.

A method for depositing silicon oxide layers having a low dielectric constant by reaction of an organosilicon compound and a hydroxyl forming compound at a substrate temperature less than about 400° C. The low dielectric constant films contain residual carbon and are useful for gap fill layers, pre-metal dielectric layers, inter-metal dielectric layers, and shallow trench isolation dielectric layers in sub-micron devices. The hydroxyl compound can be prepared prior to deposition from water or an organic compound. The silicon oxide layers are preferably deposited at a substrate temperature less than about 40° C. onto a liner layer produced from the organosilicon compound to provide gap fill layers having a dielectric constant less than about 3.0.

This invention includes a wettable biomedical device containing a high molecular weight hydrophilic polymer and a hydroxyl-functionalized silicone-containing monomer.

Acrylic-based pressure sensitive adhesives are modified with a telechelic hydrocarbon oligomer. The oligomer comprises a hydrocarbon polymer chain or backbone and a functional end group, e.g., an oligomer prepared from a mono hydroxyl polybutadiene polymer and toluene diisocyanate. The oligomer attaches to the acrylic backbone of the polymer as a pendant group and in a preferred embodiment, the oligomer is mixed with the PSA shortly before the PSA is coated.

Improved methods for synthesis of oligonucleotides and other phosphorus-linked oligomers are disclosed. The methods include the use of aromatic solvents, alkyl aromatic solvents, halogenated aromatic solvents, halogenated alkyl aromatic solvents, or aromatic ether solvents to achieve deprotection of protected hydroxyl groups.

The present invention relates to a cross-linker for photoresist compositions which is suitable for a photolithography process using KrF (248 mn), ArF (193 mn), E-beam, ion beam or EUV light sources. Preferred cross-linkers, according to the present invention, comprise a copolymer of (i) a compound represented by following Chemical Formula 1 and / or (ii) one or more compound(s) selected from the group consisting of acrylic acid, methacrylic acid and maleic anhydride. ##STR1## wherein, R.sub.1 and R.sub.2 individually represent straight or branched C.sub.1-10 alkyl, straight or branched C.sub.1-10 ester, straight or branched C.sub.1-10 ketone, straight or branched C.sub.1-10 carboxylic acid, straight or branched C.sub.1-10 acetal, straight or branched C.sub.1-10 alkyl including at least one hydroxyl group, straight or branched C.sub.1-10 ester including at least one hydroxyl group, straight or branched C.sub.1-10 ketone including at least one hydroxyl group, straight or branched C.sub.1-10 carboxylic acid including at least one hydroxyl group, and straight or branched C.sub.1-10 acetal including at least one hydroxyl group; and R.sub.3 represents hydrogen or methyl.

The present invention is directed to conjugates such as polymeric prodrugs of aromatic, hydroxyl-containing compounds and methods of making and using the same. These polymeric prodrugs are preferably esters of hydroxyl-containing aromatic compounds and are formed by reacting a desired aromatic, hydroxyl-containing compound with a substantially non-antigenic polymer so as to produce a transport form having an ester linkage between the aromatic compound and the polymer. Preferred aromatic hydroxyl-containing compositions include 10- and 11-hydroxycamptothecin derivatives. Methods of treatment are also disclosed.

A composition is provided which is useful for self-tanning skin coloring and is characterized by improved stability, which comprises from about 0.5% to about 20.0% by weight, based on total weight of said composition, of a self-tanning skin coloring agent subject to chemical instability, which is preferably dihydroxyacetone; from about 2.0% to about 40.0% by weight of a polyethoxyglycol, which is preferably ethoxydiglycol; and from about 0.1% to about 15.0% by weight of a polyol comprising a polyhydric compound having at least three hydroxyl groups and at least three carbon atoms, which is preferably D-sorbitol. The self-tanning composition may further optionally contain from about 0.1% to about 8.0% by weight of a water soluble dihydroxyl compound having at least two, and up to eight carbon atoms, which is preferably ethylene glycol; and the self-tanning composition may still further optionally contain an acidifying agent in amount sufficient to maintain the pH of said total composition at from about 3.5 to about 4.5, which is preferably sorbic acid. Cosmetologic products and methods of tanning are also provided.

In one aspect, the invention is formulations comprising both organoaminohafnium and organoaminosilane precursors that allows anchoring both silicon-containing fragments and hafnium-containing fragments onto a given surface having hydroxyl groups to deposit silicon doped hafnium oxide having a silicon doping level ranging from 0.5 to 8 mol %, preferably 2 to 6 mol %, most preferably 3 to 5 mol %, suitable as ferroelectric material. In another aspect, the invention is methods and systems for depositing the silicon doped hafnium oxide films using the formulations.

The present invention provides a room temperature-setting composition containing a polyoxyalkylene polymer (A), having a molecular weight of from 8000 to 50000 and having hydrolyzable silicon groups of the following formula (1), which comprises, as an essential component, the polyoxyalkylene polymer, having a molecular weight of from 8000 to 50000 and having hydrolyzable silicon groups of the formula (1), wherein a is 3 and a room temperature-setting composition containing a polyoxyalkylene polymer (A) having a molecular weight of from 8000 to 50000 and having hydrolyzable silicon groups of the formula (1), which comprises, as essential components, the polyoxyalkylene polymer having a molecular weight of from 8000 to 50000 and having hydrolyzable silicon groups of the formula (1) wherein a is 3, and a polymer (B) made by polymerization of a polymerizable unsaturated group-containing monomer (C):wherein R1 is a C1-20 substituted or unsubstituted monovalent organic group, X is a hydroxyl group or a hydrolyzable group, a is 1, 2 or 3, provided that when more than one R1 exist, the plurality of R1 may be the same or different, and when more than one X exist, the plurality of X may be the same or different.

A polycarboxy binder composition that contains a dextrin as a co-binder is provided. The dextrin co-binder may be a dextrin, a modified dextrin, a maltodextrin, or combinations thereof. The dextrin may be chemically modified. A pre-binder composition is formed that contains a polycarboxy polymer, a crosslinking agent, and optionally a catalyst. The polycarboxy polymer may be a homopolymer or copolymer prepared from unsaturated carboxylic acids and may be modified to contain one or more vinyl compounds. The crosslinking agent may be a polyol that contains at least two hydroxyl groups. The pre-binder composition may be formed by admixing the polycarboxy polymer, the crosslinking agent, and optionally, the catalyst, in a mixing device. Dextrin may be added to the pre-binder composition in an amount of from 10-75% of the total binder composition. The dextrin binder composition may have a ratio of from approximately 90:10 to 25:75 pre-binder:dextrin co-binder.

The present invention provides a reliable, long-life phosphor, or the like, which is prevented from darkening due to aging. A light emitting apparatus has a light emitting element and a phosphor layer. The phosphor layer has a phosphor excited by light from the light emitting element, and a binder which binds the phosphor. The binder is hydroxide oxide gel obtained by curing sol of a hydroxide oxide mixed with sol containing at least one metallic element selected from the group consisting of Al, Y, Gd, Lu, Sc, Ga, In, and B. Transmittance of hydroxide oxide in a gel state is higher than the transmittance in the polycrystal state where the sol-gel reaction is proceeded. In addition, the content of hydroxyl group or water of crystallization in the hydroxide oxide is 10% or less by weight.

Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and / or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

Micro-mechanical devices, such as MEMS, having layers thereon, and methods of forming the layers, are disclosed. In one aspect, a method may include forming a layer including an oxide of aluminum over at least a portion of a micro-mechanical device, and coating the layer by bonding material to surface hydroxyl groups of the layer. In another aspect, a method may include introducing a micro-mechanical device into an atomic layer deposition chamber, and substantially filling nanometer sized voids of the micro-mechanical device by using atomic layer deposition to introduce material into the voids. In a still further aspect, a method may include introducing an alkylaminosilane to a micro-mechanical device having a surface hydroxyl group, and bonding a silane to the micro-mechanical device by reacting the alkylaminosilane with the surface hydroxyl group.

Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and / or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and / or diseases associated with aldosterone excess.

The invention includes processes for combined polymer surface treatment and metal deposition. Processes of the invention include forming an aqueous solution containing a metal activator, such as an oxidized species of silver, cobalt, ruthenium, cerium, iron, manganese, nickel, rhodium, or vanadium. The activator can be suitably oxidized to a higher oxidation state electrochemically. Exposing a part to be plated (such as an organic resin, e.g. a printed circuit board substrate) to the solution enables reactive hydroxyl species (e.g. hydroxyl radicals) to be generated and to texture the polymer surface. Such texturing facilitates good plated metal adhesion. As part of this contacting process sufficient time is allowed for both surface texturing to take place and for the oxidized metal activator to adsorb onto said part. The part is then contacted with a reducing agent capable of reducing the metal activator to a lower ionic form, or a lower oxidation state. That reduction can result in the formation of metallic catalytic material over the surface of the part. The reduced metal activator can then function to catalyze the electroless deposition of metal such as copper from solution by contacting the part with the plating solution.

A process for preparing a polymer having a 2,5-furandicarboxylate moiety within the polymer backbone and having a number average molecular weight of at least 10,000 (as determined by GPC based on polystyrene standards) includes a first step where a prepolymer is made having the 2,5-furandicarboxylate moiety within the polymer backbone, followed in a second step by a polycondensation reaction. In the first step a 2,5-furandicarboxylate ester is transesterified with a compound or mixture of compounds containing two or more hydroxyl groups, in the presence of a tin(IV) based transesterification catalyst. In the second step at reduced pressure and under melt conditions the prepolymer prepared in the first step is polycondensed in the presence of a tin (II) based polycondensation catalyst until the polymer is obtained. This polymer may then be subjected to Solid State Polycondensation. Polymers so produced may have a 2,5-furandicarboxylate moiety within the polymer backbone, and having a number average molecular weight of at least 20,000 (as determined by GPC based on styrene standards), and an absorbance as a 5 mg / mL solution in a dichloromethane:hexafluoroisopropanol 8:2 at 400 nm of below 0.05.

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.

A biodegradable and biocompatible polyurethane composition synthesized by reacting isocyanate groups of at least one multifunctional isocyanate compound with at least one bioactive agent having at least one reactive group —X which is a hydroxyl group (—OH) or an amine group (—NH2). The polyurethane composition is biodegradable within a living organism to biocompatible degradation products including the bioactive agent. Preferably, the released bioactive agent affects at least one of biological activity or chemical activity in the host organism. A biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is preferably derived from a diurea diol or a diester diol and is preferably biodegradable into biomolecule degradation products or into biomolecule degradation products and a biocompatible diol. Another biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is derived from a diurethane diol and is biodegradable into biomolecule degradation products.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

The present invention provides a reactive diluent composition which overcomes drawbacks of both the radical-cure and the cationic-cure reactive diluents and can be applied in a broad variety of uses such as paints, inks, adhesives, pressure sensitive adhesives, surface-modifiers, and molding materials; a curable resin composition containing the same; an activated energy ray-curable resin composition; and an activated energy ray-curable ink composition for ink-jet printing. A reactive diluent composition comprising a vinyl ether group-containing (meth)acrylic ester represented by the following general formula (1): CH2=CR<1>-COO-R<2>-O-CH=CH-R<3> (1) wherein R<1 >represents a hydrogen atom or a methyl group; R<2 >represents an organic residue of 2 to 20 carbon atoms; R<3 >represents a hydrogen atom or an organic residue of 1 to 11 carbon atoms and a hydroxyl group-containing polymerizable compound and / or divinyl ether.

A hydrocarbyldithiomethyl-modified compound of the Formula:R1—O—CH2—S—S—R2or a salt thereof wherein R1 is an organic molecule and R2 is a hydrocarbyl is useful for protecting and / or blocking hydroxyl groups in organic molecules such as nucleotides. The hydrocarbyldithiomethyl-modified compounds can also be used for chemically synthesizing oligonucleotides and for sequencing nucleic acid compounds.

The invention is directed to structuring systems suitable for incorporation into liquid fabric treatment compositions. Such structuring systems comprise, as added components, (A) a non-polymeric, crystalline, hydroxyl-containing structuring agent, which can crystallize to form a thread-like structuring network throughout liquid matrices; (B) a nonionic emulsifier; (C) an anionic emulsifier; and (D) a liquid carrier. The anionic emulsifier is present in such structuring systems, at concentrations from 0.1% to 8.0% by weight of the structuring system. The present invention also relates to processes for preparing such structuring systems and to the use of the structuring system of the present invention to control the particle size of a thread-like structuring material by mixing an anionic emulsifier with a structuring agent. Liquid fabric treatment compositions containing such structuring systems are also disclosed.

A process for the production of a branched aromatic polycarbonate that includes adding a branching agent to a polycarbonate oligomer, and producing a branched aromatic polycarbonate having a melt index ratio greater than an aromatic polycarbonate produced from the polycarbonate oligomer without the addition of the branching agent. The branching agent has the formula (I):wherein A is a C1-20 polymethylene, C2-20 alkylene or alkylidene, C5-36 cycloalkylene or cycloalkylidene, C6-36 arylene or alkylarylene, or C3-36 arylalkylene, wherein G is a monovalent C6-C30 hydrocarbon having at least one hydroxyl group bonded directly to an aromatic or cycloaliphatic ring and y is an integer greater than 2, and wherein each G may be the same or different.

Methods for preparing polyurethane flexible foam are described, wherein an organic polyisocyanate is reacted with an active hydrogen-containing component such as an organic polyol, in the presence of a urethane catalyst, a blowing agent, optionally a cell opener, and a siloxane-based surfactant composition as a stabilizer for the foam. The siloxane-based surfactant composition comprises a silanol-functionalized organosiloxane having general formula (I), wherein: the R groups are independently a C1-C3 alkyl, phenyl, or —OSi(R)3; provided that at least one R group is a hydroxyl (—OH) bonded directly to any silicon atom and X is an integer from 0-200.

The preparation process of phenolic hydroxyl group-containing polyimide powder includes the following steps: 1. reaction of phenolic hydroxyl group-containing aromatic diamine compound or its mixture with other diamine compound and aromatic binary anhydride in the molar ratio of 1 to 1 in strong polar non-protonic organic solvent under protection of nitrogen at 0-30 deg.c for 3-12 hr to obtain transparent ropy polyhydroxy amido acid solution; and 2. adding azeotropic dewatering agent in nitrogen atmosphere and heating to 120-160 deg.c to reflux, azeotropically dewater and imidize for 5-18 hr, cooling to room temperature, washing and vacuum drying to obtain phenolic hydroxyl group-containing polyimide powder. The industrial production process has environment friendship, simple operation, low cost and easy solvent recovery.

Compounds of formula (I):wherein R1 is hydroxyl or sulfonamide derivative; R2 is t-butyl or —CH2—C(CH3)3 or —CH2-cyclopentyl; R3 is t-butyl or cyclohexyl and R4 is cyclobutyl, cyclopentyl or cyclohexyl; or a pharmaceutically acceptable salt thereof, are described as useful as inhibitor of the HCV NS3 protease.

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and / or diseases associated with aldosterone excess.

Disclosed is a polycarbonate composition and process from making same, wherein introduction of a chain terminator and an acyl halide other than phosgene is after at least 25 percent of the hydroxyl groups in the dihydric phenol have been converted to chloroformate groups.